{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-076809","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2026-06-23T20:02:33+00:00","discovered_at":"2026-06-23T20:04:00.815504+00:00","generated_at":"2026-06-23T20:04:23.292573+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verastem's VS-7375 shows 93% CA19-9 reduction in PDAC; plans Phase 3 in 1H2027","bullets":["93% (13/14) of heavily pretreated mPDAC patients at 900mg QD achieved >50% reduction in CA19-9; all remain on treatment.","VS-7375 900mg QD achieved target plasma levels with clear PK separation from 600mg; safety profile favorable with low-grade GI AEs attenuating after cycle 1.","Dose-dependent anti-tumor activity across PDAC, mCRC, and NSCLC; combination with cetuximab or Gem/NabP shows combinability without overlapping toxicities.","Intends to collaborate with Erasca (ERAS) to evaluate VS-7375 + ERAS-0015 in preclinical models; future clinical trial collaboration possible.","Key milestones: complete Phase 1/2 enrollment by June 2026; first patient in Phase 2 registration trials mid-2026; FDA meeting by end of 2026; Phase 3 start 1H2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-076809","json":"https://secwatch.observer/filing/0001104659-26-076809.json","markdown":"https://secwatch.observer/filing/0001104659-26-076809.md","text":"https://secwatch.observer/filing/0001104659-26-076809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465926076809/0001104659-26-076809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465926076809/tm2618546d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T20:04:23.292573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}